ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
BGNE Company Profile and Key Details
BeiGene, Ltd.
Price Chart
Stock Price Today
BeiGene, Ltd. (BGNE) stock surged +0.49%, trading at $184.71 on NASDAQ, up from the previous close of $183.81. The stock opened at $184.00, fluctuating between $183.91 and $187.42 in the recent session.
Stock Snapshot
Relevant Articles
SEC Fillings
Current Report (8-k)
Annual Report (10-k)
Stock Price History Chart
Contact Details
About Company
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Company Information
| Employees | 10600 |
| Beta | 0.63 |
| Sales or Revenue | $2.46B |
| 5Y Sales Change% | 5.588% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Executive Director of Corporation Affairs
Dr. Yan Qi
Senior Vice President & Head of Public Affairs - Greater China
Mr. Wang Lai
Global Head of R&D
Mr. Graham Hardiman
Global Head of HR
Dr. Xiaobin Wu Ph.D.
Pres & Chief Operating Officer
Dr. Xiaodong Wang Ph.D.
Co- Chairman of Scientific Advisory Board & Non-Executive Director Co-Founder
Ms. Julia Wang
Chief Financial Officer & Principal Accounting Officer
Mr. Daniel Maller
Vice President of Fin. & Accounting
Mr. John V. Oyler
Co-Founder, Executive Chairman & Chief Executive Officer
Ms. Liza Heapes
Head of Investor Relations
Mr. Chan Lee
Gen. Counsel & Senior Vice President
Ms. Diana Lee Francis
Vice President and Global Head of Quality & Regulatory Compliance
Ms. Mi Zhou
Senior Director of Investor Relations
Dr. Mark Lanasa
Senior Vice President & Chief Medical Officer for Solid Tumors
Mr. Jason W. Radford
Senior Vice President of Strategy & Corporation Devel.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep